BASIS-TECHNOLOGIES
28.4.2016 14:03:46 CEST | Business Wire | Press release
Basis Technologies today announces the introduction of Consolidator, a new addition to its extensive range of automation tools. Consolidator performs the technical analysis and merge of SAP ECC systems, including those running on HANA, with minimal user intervention. Automation reduces the risk and cost of the overall process, allowing more businesses to realize the benefits of SAP system consolidation.
A time of change
Sixty-four percent of IT and marketing executives recently surveyed by Gartner said that they expect to transform into a digital business by the end of 20171 .
In such a dynamic, disruptive environment, business initiatives like digital transformation are becoming commonplace. A shift to cloud-based Enterprise Resource Planning (ERP) solutions, including S/4HANA from SAP, is also underway, and M&A activity continues to gather pace. Meanwhile, potentially huge opportunities lurk inside inefficient SAP system landscapes built up over decades of acquisitions and reorganizations.
All of these factors are combining to generate an ever-increasing level of demand for SAP system consolidation projects.
A new way to unlock value
To date, a limited number of tools have been available to support system consolidation. This has resulted in processes which feature an unavoidably high level of manual effort, with the corresponding business risk that such methods naturally bring.
Consolidator offers the chance to automate a critical - and labor-intensive - portion of the consolidation process: the technical merge. Risk and necessary resource inputs are dramatically reduced, enabling businesses to unlock value, focus on innovation, reduce cost of ownership and prepare for a new generation of enterprise solutions.
"Businesses should give more thought to optimization of the SAP systems that enable great customer experiences. Too much cash is being wasted on simply maintaining existing processes and stabilizing legacy infrastructure." said Martin Metcalf, Chief Executive Officer of Basis Technologies. "There is just not enough focus placed on unlocking the latent value within these assets through the use of automation technologies such as Consolidator"
To learn more about Consolidator, visit www.basistechnologies.com/consolidator
About Basis Technologies
Basis Technologies have delivered innovative software solutions for SAP for almost 20 years. We focus on automation tools that enable continuous delivery, helping our customers to keep pace with theirs. Our products support the adoption of methodologies such as Agile and DevOps in an SAP environment, and our client list includes a selection of major multinational companies such as BP, Unilever and Ralph Lauren.
To find out more, visit www.basistechnologies.com .
####
1. Navigate Your Way to Digital Business Transformation With These Resources, Don Scheibenreif, VP Distinguished Analyst, Gartner (August 2015)
2. Consolidator does not support the analysis or merge of transactional or master data. Other tools may be required.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160428005020/en/
Contact:
Basis Technologies
Peter Yabsley
Head of Product Marketing
+44
7867 335 310
peter.yabsley@basistechnologies.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom